- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06499727
HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men
January 21, 2026 updated by: University of Zurich
HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men: A Randomized, Placebo-Controlled, Double-Blind Parallel Trial
Millions of people travel to high altitude for work or leisure activities and are exposed to reduced inspiratory oxygen partial pressure and hypoxemia that may lead to altitude illness, among which the most common form is acute mountain sickness (AMS).
The main AMS symptoms are headache, malaise, weakness, and fatigue.
Prospective studies have shown that 20-60% of newcomers at 2500-4000m develop AMS requiring them to take medications, while, at very high altitudes, AMS may progress to high altitude cerebral oedema.
Whether women are more susceptible to AMS remains insufficiently understood since no prospective study controlled for sex hormones, use of hormone contraception or assessed menstrual cycle phase (MCP) at altitude.
Therefore, women remain underrepresented and poorly characterized in high altitude studies.
In addition, the efficacy and safety of 250 mg/day acetazolamide, the standard recommendation for AMS prevention, has never been compared between sexes, although, women have presumably higher acetazolamide plasma concentration due to lower blood volume.
Given the known dose-dependent preventive but also side effects of acetazolamide and equal proportion of women and men among mountain travellers, there is an urgent need to conclusively quantify the efficacy and safety of pre-ventive acetazolamide therapy against AMS in women compared to men.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
303
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gorod Bishkek
-
Bishkek, Gorod Bishkek, Kyrgyzstan, 720040
- National center for cardiology and internal medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy, non-smoking men and women, age 18-44 years, without any disease and need of regular medication (including oral contraceptives).
- BMI >18 kg/m2 and <30 kg/m2
- Born, raised and currently living at altitudes <1000 m
- Written informed consent
- Premenopausal women with an eumenorrheic cycle
Exclusion Criteria:
- Other types of contraceptvies (contraceptives (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others)
- Pregnancy or nursing
- Anaemic (haemoglobin concentration <10g/dl)
- Any altitude trip <4 weks before the study
- Allergy to acetazolamide and other sulfonamides
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: WOMEN - ACETAZOLAMIDE oral capsule
Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
|
|
Active Comparator: MEN - ACETAZOLAMIDE oral capsule
Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
|
|
Placebo Comparator: WOMEN - PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
|
|
Placebo Comparator: MEN - PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Mountain Sickness (AMS) Incidence, LLS 2018
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the incidence of AMS.
AMS incidence will be defined as a Lake Louise Questionnaire version 2018 score of ≥3.
|
Day 1 to 3 at 3600 m
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Mountain Sickness (AMS) Incidence, LLS 1993
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the incidence of AMS.
AMS incidence will be defined as a Lake Louise Questionnaire version 1993 score of ≥3.
|
Day 1 to 3 at 3600 m
|
|
Acute Mountain Sickness (AMS) Severity, LLS 2018
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the AMS severity assessed by the Lake Louise Questionnaire version 2018.
|
Day 1 to 3 at 3600 m
|
|
Acute Mountain Sickness (AMS) Severity, LLS 1993
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the AMS severity assessed by the Lake Louise Questionnaire version 1993.
|
Day 1 to 3 at 3600 m
|
|
Drug-related side effects
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the incidence and severity of medication side effects.
|
Day 1 to 3 at 3600 m
|
|
Arterial blood gases
Time Frame: Day 2 at 760 m and day 2 at 3600 m
|
Sex-related differences between acetazolamide and placebo group in the arterial blood gases (pH, PaO2, PaCO2, SaO2).
|
Day 2 at 760 m and day 2 at 3600 m
|
|
Acetazolamide plasma concentration
Time Frame: Day 2 at 3600 m
|
Sex-related differences between acetazolamide plasma concentration assessed by dried blood spots.
|
Day 2 at 3600 m
|
|
Hypoxic ventilatory response
Time Frame: Day 2 at 760 m
|
Sex-related difference in the hypoxic ventilatory response assessed under FiO2 of 0.115 and while cycling on a bicycle at 30% of predicted maximal work capacity.
|
Day 2 at 760 m
|
|
Perceived pain visualization
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related differences between acetazolamide and placebo group on perceived pain sensations, visualized by the SMaRT tablet app
|
Day 1 to 3 at 3600 m
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Michael Furian, Prof. Dr., University of Zurich
- Study Director: Talant Sooronbaev, Prof. Dr., National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 15, 2024
Primary Completion (Actual)
August 31, 2025
Study Completion (Actual)
August 31, 2025
Study Registration Dates
First Submitted
July 5, 2024
First Submitted That Met QC Criteria
July 11, 2024
First Posted (Actual)
July 12, 2024
Study Record Updates
Last Update Posted (Actual)
January 23, 2026
Last Update Submitted That Met QC Criteria
January 21, 2026
Last Verified
May 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Hypoxia
- Altitude Sickness
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Thiazoles
- Azoles
- Thiadiazoles
- Acetazolamide
Other Study ID Numbers
- HighCycle_AMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.